Previous close | 0.2000 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 4.8000 |
Strike | 65.00 |
Expiry date | 2024-06-21 |
Day's range | 0.2000 - 0.2000 |
Contract range | N/A |
Volume | |
Open interest | 2 |
Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.
Terns Pharmaceuticals, Inc. (TERN) outperforms the industry year to date on encouraging pipeline progress of its oncology candidate.
Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND ) shareholders should be happy to see the share price up 10% in the...